

# Scott A North

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9301416/scott-a-north-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113  
papers

9,858  
citations

35  
h-index

99  
g-index

117  
ext. papers

11,621  
ext. citations

5.1  
avg, IF

5.19  
L-index

#	Paper	IF	Citations
113	Abiraterone and increased survival in metastatic prostate cancer. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 1995-2005	59.2	3019
112	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5794-9	2.2	1390
111	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , <b>2012</b> , 13, 983-92	21.7	965
110	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 121-131	59.2	479
109	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , <b>2017</b> , 72, 544-554	10.2	411
108	The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. <i>Journal of Urology</i> , <b>2011</b> , 185, 60-6	2.5	258
107	A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. <i>Cancer</i> , <b>2007</b> , 110, 1959-66	6.4	252
106	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology</i> , <b>2012</b> , 13, 1210-7	21.7	225
105	Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4247-54	2.2	195
104	Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). <i>European Urology</i> , <b>2014</b> , 66, 815-25	10.2	186
103	Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , <b>2015</b> , 67, 241-9	10.2	178
102	Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , <b>2013</b> , 119, 2999-3006	6.4	144
101	Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5765-73	12.9	110
100	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology</i> , <b>2012</b> , 13, 927-35	21.7	104
99	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6487-6497	12.9	81
98	Associations between exercise and quality of life in bladder cancer survivors: a population-based study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2007</b> , 16, 984-90	4	77
97	Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. <i>Urology</i> , <b>2010</b> , 76, 430-4	1.6	72

96	The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , <b>2015</b> , 9, 90-6	1.2	70
95	Exercise programming and counseling preferences in bladder cancer survivors: a population-based study. <i>Journal of Cancer Survivorship</i> , <b>2007</b> , 1, 27-34	5.1	68
94	Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. <i>Expert Review of Vaccines</i> , <b>2005</b> , 4, 249-57	5.2	64
93	Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, e79-85	3.3	59
92	The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , <b>2014</b> , 65, 723-30	10.2	59
91	Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Pharmacology</i> , <b>2015</b> , 55, 1406-14	2.9	58
90	Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. <i>European Urology</i> , <b>2014</b> , 65, 1086-92	10.2	56
89	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3181-3188	2.2	53
88	Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial. <i>Cancer</i> , <b>2017</b> , 123, 4057-4065	6.4	52
87	Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 311-5	3.3	50
86	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , <b>2013</b> , 8, 203-209	5	45
85	A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2005</b> , 23, 143-9	2.8	45
84	A prospective study of the determinants of exercise in bladder cancer survivors using the Theory of Planned Behavior. <i>Supportive Care in Cancer</i> , <b>2009</b> , 17, 171-9	3.9	42
83	Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. <i>European Urology</i> , <b>2015</b> , 68, 570-7	10.2	41
82	Associations between physical activity and quality of life in a population-based sample of kidney cancer survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2011</b> , 20, 859-68	4	40
81	Correlates of physical activity in a population-based sample of kidney cancer survivors: an application of the theory of planned behavior. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , <b>2012</b> , 9, 96	8.4	39
80	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, E46-80	1.2	39
79	A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naïve castration resistant prostate cancer. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1652-9	4.3	36

78	A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. <i>Canadian Urological Association Journal</i> , <b>2009</b> , 3, 281-289	1.2	35
77	Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). <i>Canadian Urological Association Journal</i> , <b>2013</b> , 7, E44-56	1.2	32
76	Physical activity preferences in a population-based sample of kidney cancer survivors. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 1709-17	3.9	31
75	Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. <i>Urology</i> , <b>2006</b> , 68, 565-9	1.6	30
74	Randomized controlled trial of a behavior change intervention to increase physical activity and quality of life in prostate cancer survivors. <i>Annals of Behavioral Medicine</i> , <b>2013</b> , 46, 382-93	4.5	28
73	L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2007</b> , 7, 1723-30	5.4	28
72	Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1313-1321	8.7	27
71	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, 112-117	1.2	25
70	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , <b>2020</b> , 78, 834-844	10.2	23
69	Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , <b>2016</b> , 122, 411-9	6.4	23
68	Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study. <i>Thrombosis Research</i> , <b>2003</b> , 112, 59-64	8.2	21
67	A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, e127-31	3.3	20
66	Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 354-8	3.3	20
65	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , <b>2019</b> , 108, 69-77	7.5	20
64	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , <b>2019</b> , 2, 643-648	6.7	19
63	A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 201-208.e1	3.3	18
62	Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. <i>Canadian Urological Association Journal</i> , <b>2013</b> , 7, 312-8	1.2	17
61	Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 328-334	2.8	16

60	A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. <i>Canadian Urological Association Journal</i> , <b>2009</b> , 3, 369-74	1.2	16
59	Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , <b>2021</b> , 18, 104-114	5.5	16
58	Social-ecological correlates of physical activity in kidney cancer survivors. <i>Journal of Cancer Survivorship</i> , <b>2016</b> , 10, 164-75	5.1	15
57	The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study. <i>Bladder Cancer</i> , <b>2018</b> , 4, 185-194	1	15
56	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , <b>2015</b> , 9, 164-70	1.2	15
55	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 3.e17-3.e27	2.8	15
54	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 403-410.e2	3.3	12
53	Management of urachal cancer: A consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E57-E64	1.2	12
52	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, 309-16	1.2	12
51	CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. <i>Canadian Urological Association Journal</i> , <b>2013</b> , 7, 231-7	1.2	12
50	A randomized, phase III, double-blind, placebo-controlled trial of intrapleural instillation of methylprednisolone acetate in the management of malignant pleural effusion. <i>Chest</i> , <b>2003</b> , 123, 822-7	5.3	12
49	Associations between sitting time and quality of life in a population-based sample of kidney cancer survivors. <i>Mental Health and Physical Activity</i> , <b>2013</b> , 6, 16-23	5	10
48	Feasibility and preliminary efficacy of adding behavioral counseling to supervised physical activity in kidney cancer survivors: a randomized controlled trial. <i>Cancer Nursing</i> , <b>2014</b> , 37, E8-22	2.6	10
47	The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. <i>BJU International</i> , <b>2008</b> , 102, 551-5	5.6	10
46	Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. <i>European Urology</i> , <b>2021</b> , 80, 693-700	10.2	10
45	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 150-5	3.3	9
44	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , <b>2019</b> , 13, 307-314	1.2	9
43	Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, e287-93	1.2	9

42	Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2013</b> , 36, 601-5	2.7	9
41	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 331-40	3.3	9
40	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , <b>2019</b> , 13, 343-354	1.2	8
39	A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. <i>Oncotarget</i> , <b>2018</b> , 9, 8155-8164	3.3	8
38	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 639.e1-639.e9	2.8	7
37	First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 335-40	3.3	7
36	A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, E583-90	1.2	7
35	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2100941	2.2	7
34	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, 310-320	1.2	6
33	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 12, E281-E297	1.2	6
32	Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. <i>Canadian Urological Association Journal</i> , <b>2013</b> , 7, 238-43	1.2	6
31	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. <i>Canadian Urological Association Journal</i> , <b>2019</b> , 318-327	1.2	5
30	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	5
29	Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy. <i>Journal of Urology</i> , <b>2014</b> , 191, 35-9	2.5	5
28	Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?. <i>Canadian Urological Association Journal</i> , <b>2008</b> , 2, 222-4	1.2	5
27	Outcome of advanced stage low grade follicular lymphomas in a population-based retrospective cohort. <i>Cancer</i> , <b>1999</b> , 85, 1361-8	6.4	5
26	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , <b>2021</b> , 15, E81-E90	1.2	4
25	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E373-E382	1.2	3

24	Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e637-e644	3.3	3
23	Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). <i>Investigational New Drugs</i> , <b>2016</b> , 34, 771-776	4.3	3
22	Changes in motivational outcomes following a supervised physical activity program with behavioral counseling in kidney cancer survivors: a pilot study. <i>Psycho-Oncology</i> , <b>2015</b> , 24, 1204-7	3.9	3
21	A phase II trial of weekly i.v. KW-2170 in advanced castrate-resistant prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2010</b> , 6, 292-7	1.9	3
20	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , <b>2021</b> , 80, 275-279	10.2	3
19	Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. <i>Journal of Oncology Pharmacy Practice</i> , <b>2019</b> , 25, 1293-1300	1.7	2
18	Small cell carcinoma of the genitourinary tract: A 10-year single institution experience.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 312-312	2.2	2
17	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , <b>2021</b> , 39, 4345-4354	4	2
16	The role of the built environment in a randomized controlled trial to increase physical activity among men with prostate cancer: the PROMOTE trial. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 2993-2996	3.9	1
15	Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2020</b> , 43, 559-566	2.7	1
14	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , <b>2021</b> , 15, 84-97	1.2	1
13	Patterns of cost-related medication underuse among Canadian adults with cancer: a cross-sectional study using survey data. <i>CMAJ Open</i> , <b>2021</b> , 9, E474-E481	2.5	1
12	Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E115-E125	1.2	1
11	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , <b>2021</b> , 127, 528-537	5.6	1
10	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. <i>Bladder Cancer</i> , <b>2020</b> , 6, 363-392	1	0
9	Perioperative chemotherapy for muscle invasive bladder cancer. <i>Current Opinion in Supportive and Palliative Care</i> , <b>2015</b> , 9, 249-54	2.6	0
8	The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review. <i>Oncologist</i> , <b>2021</b> , 26, e1381-e1394	5.7	0
7	The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy.. <i>Therapeutic Advances in Medical Oncology</i> , <b>2022</b> , 14, 1758835922109487	5.4	0

6	High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinoma. <i>Clinical Nutrition</i> , <b>2018</b> , 37, 1070-1072	5.9
5	Socioeconomic disparities in the prevalence of comorbid chronic conditions among Canadian adults with cancer. <i>Acta Oncologica</i> , <b>2021</b> , 1-8	3.2
4	Dr. North's rebuttal. <i>Canadian Urological Association Journal</i> , <b>2008</b> , 2, 228	1.2
3	Assessing the utility of cabazitaxel in mCRPC. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, 111-2	1.2
2	Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). <i>Journal of Cancer Education</i> , <b>2019</b> , 34, 14-18	1.8
1	Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.. <i>Journal of Medical Economics</i> , <b>2022</b> , 1-32	2.4